{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:16:14Z","timestamp":1777936574785,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Abiraterone acetate is an androgen synthesis inhibitor approved for the treatment of castration-resistant prostate cancer (CRPC). Although co-administration of either prednisone or prednisolone at 10\u2009mg\/d has been recommended to reduce the risk of abiraterone-induced hyperaldosteronism (notably hypokalemia) and to give adjunctive pain relief effects, whether these glucocorticoids can be substituted by dexamethasone remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective review of medical records of patients who were given abiraterone for the treatment of CRPC with either prednisolone (ABI\/PSL) 10\u2009mg\/d or dexamethasone (ABI\/DEX) 0.5 or 1\u2009mg\/d between 2014 and 2017 in Juntendo University Nerima Hospital. Demographic and biochemical data including prostate-specific antigen (PSA) level were retrieved from the electronic medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-three eligible patients (27 in ABI\/PSL group and 26 in ABI\/DEX group) were extracted from the records. Both groups showed no significant changes in serum potassium level before and after starting treatment. In the ABI\/PSL group, 12 patients (46%) showed elevations of PSA and 7 patients (27%) discontinued treatment within 3\u2009months. In contrast, in the ABI\/DEX group, only 6 patients (25%) showed elevations of PSA and 3 patients (13%, all were given dexamethasone 1\u2009mg\/d) discontinued treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dexamethasone and prednisolone may be equally effective in preventing abiraterone-induced hypokalemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1179554917737736","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T02:19:04Z","timestamp":1509416344000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Consequences of Different Corticosteroids on Serum Potassium and Prostate-Specific Antigen in Patients Receiving Abiraterone for Castration-Resistant Prostate Cancer: A Retrospective Observational Study"],"prefix":"10.1177","volume":"11","author":[{"given":"Masaomi","family":"Tatsuzawa","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kinjo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Urology, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyo","family":"Shimojima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Echizen","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Juntendo University Nerima Hospital, Tokyo, Japan"},{"name":"Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"bibr1-1179554917737736","unstructured":"Zytiga (abiraterone acetate). Tablets prescribing information. https:\/\/www.zytiga.com\/shared\/product\/zytiga\/zytiga-prescribing-information.pdf. Accessed April 19, 2017."},{"key":"bibr2-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"bibr3-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3332"},{"key":"bibr4-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0249"},{"key":"bibr5-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0642"},{"key":"bibr6-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749"},{"key":"bibr7-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.6819"},{"key":"bibr8-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2189"},{"key":"bibr9-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"bibr10-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12589"},{"key":"bibr11-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu148"},{"key":"bibr12-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.5.590"},{"key":"bibr13-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H"},{"key":"bibr14-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2001.00302.x"},{"key":"bibr15-1179554917737736","first-page":"479","volume":"91","author":"Kobayashi T","year":"2000","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"bibr16-1179554917737736","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0","author":"US Department of Health and Human Services; National Cancer Institute","year":"2009"},{"key":"bibr17-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"bibr18-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.531"},{"key":"bibr19-1179554917737736","first-page":"1209","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","volume":"2011","author":"Schimmer BPF","edition":"12"},{"key":"bibr20-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.11.012"},{"key":"bibr21-1179554917737736","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.004"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1179554917737736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1179554917737736","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1179554917737736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:36:50Z","timestamp":1777693010000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1179554917737736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":21,"alternative-id":["10.1177\/1179554917737736"],"URL":"https:\/\/doi.org\/10.1177\/1179554917737736","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,1]]},"article-number":"1179554917737736"}}